4 results about "NK cell proliferation" patented technology

The invention discloses a traditional Chinese medicine compound cell culture fluid and application thereof. The traditional Chinese medicine compound cell culture fluid comprises a basic culture medium, and 1 L of the basic culture medium contains 2-10 mg of notoginsenoside R1, 1-5 mg of notoginsenoside Rb1, 1-5 mg of notoginsenoside Rg1, 0.1-1 mg of notoginsenoside Rg3, 0.5-2 mg of notoginsenoside Re, 1-6 [mu] g of shikonin, 5-15 [mu] g of cordycepin and 1-20 mg of basil polysaccharide. In the traditional Chinese medicine compound cell culture fluid, notoginsenoside Rg3 can be combined with shikonin, so that the cytotoxicity can be enhanced, cord blood NK cells are promoted to be differentiated to mature functional phenotypes with high cytotoxic activity, and the killing efficiency of the NK cells on various tumor target cells is remarkably improved; the notoginsenoside Rb1 is combined with the basil polysaccharide, so that the NK cells can be driven to expand and grow, the activity of the NK cells can be maintained, and the cell purity can be improved, so that the persistence of the cell activity can be enhanced, and the tumor killing rate of the NK cells can be improved.

The present application belongs to the field of cell culture. The present application provides a method for inducing, culturing and amplifying human natural killer cells, comprising the following steps: extracting peripheral blood from a healthy person, and separating PBMC; coating a container with an NK activation solution; culturing with an NK cell proliferation medium, inoculating PBMC, and incubating at a constant temperature for 1-6 days; and proliferating with an NK cell amplification medium, and incubating at a constant temperature for 1-10 days. The present application effectively improves the in-vitro proliferation rate of human natural killer cells. Through flow cytometry analysis, the proportion of NK cells with phenotypes of CD3, CD16 and CD56 in the cell population is all above 80%, and the cell phenotype is CD56 + CD3 ‑ NK cell group, and the positive rate is 97.57%. The present application has a simple composition formula, ideal culture effect, and wide application prospect.

This invention relates to proteins targeting B7H3 and methods of using them. Multispecific B7H3-targeting compounds and methods of using them are provided. These multispecific compounds include bispecific and trispecific targeting proteins. The bispecific targeting protein includes a B7H3 targeting domain and an immune cell binding domain; the trispecific targeting protein includes a B7H3 targeting domain, an immune cell binding domain, and an immune cell activation domain. These methods of use include methods for inducing NK-mediated cell killing, methods for inducing NK cell proliferation in vivo, and methods for treating cancer.

This invention relates to the field of immune cell culture technology, and particularly to a method for in vitro culture of peripheral blood NK cells. The invention involves sequentially performing a first culture and a second culture on in vitro cultured peripheral blood NK cells. In the first culture stage, star anise extract and IL-2 are used. The active components in the star anise extract synergistically interact with IL-2 to induce an increase in NK cell activity. Furthermore, in the second culture stage, epimedium extract is used to culture the NK cells, which improves the NK cell environment and promotes rapid NK cell proliferation. The entire process requires no additional treatment and is simple. Therefore, the technical solution of this invention not only enhances the proliferation capacity of NK cells but also prolongs their original cytotoxic activity.